EGFR and non-small cell lung carcinoma: In EGFR mutant NSCLC, EGFR TKI-sensitive cells can give way to a population of TKI-resistant drug-tolerant persister (DTP) cells that will proliferate at a low rate when exposed to the drug and become the dominant clonal population after the death of rapidly proliferating EGFR-dependent cells [44].